<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE/BACKGROUND: We investigated the usefulness of a clinical risk scoring system (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e>) for guiding management and defining prognosis for patients with colorectal liver met"astases (CLM) </plain></SENT>
<SENT sid="1" pm="."><plain>METHOD: We retrospectively analyzed data about the correlation between outcomes and Fong's <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> from 1989 to 2010 for patients treated for CLM at the Severance Hospital </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Of 566 patients, 232 received adjuvant treatment after liver resection </plain></SENT>
<SENT sid="3" pm="."><plain>Of these patients, 185 (81%) had a low <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> (0-2) and 47 (19%) had a high <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> (3-5) </plain></SENT>
<SENT sid="4" pm="."><plain>Stratification into high and low <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> allowed significant distinction between Kaplan-Meier curves for outcome </plain></SENT>
<SENT sid="5" pm="."><plain>The 5-year survival rate was 88.5% and 11.5% among patients with a low and high <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e>, respectively (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Seventy patients with initially unresectable CLM underwent liver resection after <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> downsizing by induction chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>Shifting of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> from high to low (8 patients; 11.4%) improved disease-free survival and overall survival </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: High <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> is associated with worse survival after resection in resectable and unresectable disease </plain></SENT>
<SENT sid="9" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> may be used for risk assessment when recommending oncological surgical timing in initially unresectable disease and treatment options for perioperative or adjuvant treatment in resectable disease </plain></SENT>
</text></document>